About Us
WHO WE ARE
Luxa Biotechnology is a clinical-stage biotechnology company developing a novel adult RPE stem cell (RPESC) therapy for Dry AMD and Geographic Atrophy. The proprietary adult RPESC-derived RPE stem cell product was developed at and licensed from the Neural Stem Cell Institute (NSCI).
Luxa is a LLC located in NJ and was founded through a partnership of the Neural Stem Cell Institute located in NY and Y2 Solution located in Seoul, Korea. Luxa is conducting a clinical trial to test the safety and efficacy of RPESC-RPE-4W, a unique RPE progenitor stage cell product, as a potential therapy for dry AMD.
Luxa maintains a robust research program at NSCI to develop the RPESC as an effective, commercially viable cell product. The Phase 1/2a clinical trial of RPESC-RPE-4W for the Treatment of dry age-related Macular Degeneration includes the Cedars Sinai Biomanufacturing Center, Emmes, the University of Michigan Kellogg Eye Center, the National Eye Institute, Stanford Medical Center and California Institute for Regenerative Medicine.